Show simple item record

dc.contributor.authorAmanat, Fatima
dc.contributor.authorStrohmeier, Shirin
dc.contributor.authorMeade, Philip S
dc.contributor.authorDambrauskas, Nicholas
dc.contributor.authorMühlemann, Barbara
dc.contributor.authorSmith, Derek J
dc.contributor.authorVigdorovich, Vladimir
dc.contributor.authorSather, D Noah
dc.contributor.authorCoughlan, Lynda
dc.contributor.authorKrammer, Florian
dc.date.accessioned2022-01-28T16:48:05Z
dc.date.available2022-01-28T16:48:05Z
dc.date.issued2021-12
dc.identifier.issn1544-9173
dc.identifier.other34914685
dc.identifier.otherPMC8758087
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/333330
dc.descriptionFunder: open philanthropy project
dc.descriptionFunder: jpb foundation
dc.description.abstractVaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been highly efficient in protecting against Coronavirus Disease 2019 (COVID-19). However, the emergence of viral variants that are more transmissible and, in some cases, escape from neutralizing antibody responses has raised concerns. Here, we evaluated recombinant protein spike antigens derived from wild-type SARS-CoV-2 and from variants B.1.1.7, B.1.351, and P.1 for their immunogenicity and protective effect in vivo against challenge with wild-type SARS-CoV-2 in the mouse model. All proteins induced high neutralizing antibodies against the respective viruses but also induced high cross-neutralizing antibody responses. The decline in neutralizing titers between variants was moderate, with B.1.1.7-vaccinated animals having a maximum fold reduction of 4.8 against B.1.351 virus. P.1 induced the most cross-reactive antibody responses but was also the least immunogenic in terms of homologous neutralization titers. However, all antigens protected from challenge with wild-type SARS-CoV-2 in a mouse model.
dc.languageeng
dc.publisherPublic Library of Science (PLoS)
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourcenlmid: 101183755
dc.sourceessn: 1545-7885
dc.subjectAnimals
dc.subjectAntibodies, Neutralizing
dc.subjectAntibodies, Viral
dc.subjectCOVID-19
dc.subjectCOVID-19 Vaccines
dc.subjectChlorocebus aethiops
dc.subjectCross Reactions
dc.subjectFemale
dc.subjectMice
dc.subjectMice, Inbred BALB C
dc.subjectSARS-CoV-2
dc.subjectVero Cells
dc.titleVaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus.
dc.typeArticle
dc.date.updated2022-01-28T16:48:04Z
prism.issueIdentifier12
prism.publicationNamePLoS Biol
prism.volume19
dc.identifier.doi10.17863/CAM.80753
dcterms.dateAccepted2021-11-24
rioxxterms.versionofrecord10.1371/journal.pbio.3001384
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidAmanat, Fatima [0000-0002-8029-8227]
dc.contributor.orcidMühlemann, Barbara [0000-0002-5314-8530]
dc.contributor.orcidCoughlan, Lynda [0000-0001-9880-6560]
dc.contributor.orcidKrammer, Florian [0000-0003-4121-776X]
dc.identifier.eissn1545-7885
pubs.funder-project-idNational Institutes of Health (NIH) (via Mount Sinai School of Medicine (MSSM)) (HHSN272201400008C)
pubs.funder-project-idNational Institutes of Health (NIH) (via Mount Sinai School of Medicine (MSSM)) (0258-0513/HHSN272201400008C)
cam.issuedOnline2021-12-16


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International